Compound ID | 390
Synonym(s): SM-216601 | PZ-601
Class: Beta-lactam (penem)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Cell wall inhibitor; was in clinical trials for Gram positive infections |
| Description: | Young CL, Rusca A, Di Stefano AFD, Radicioni M, Binelli D, Loprete L, et al. Safety and multiple dose pharmacokinetics of intravenous PZ-601 (SMP-601): a novel carbapenem. 47th-ICAAC-2007 2007;9-10 |
| Institute where first reported: | Sumitomo Pharmaceuticals (Dainippon Sumitomo Pharma, Japan); Licensed North American rights to Protez Pharmaceuticals, US |
| Year first mentioned: | 2004 |
| Highest developmental phase: | Phase 2 |
| Development status: | Inactive |
| Reason Dropped: | Adverse effects (S1, 1) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/10993211 |
| Guide to Pharmacology: | razupenem |
| Citation: |